Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Galen Estrogen Ring Will Be Marketed By Warner Chilcott 260-Rep Force

  • News

Executive Summary

Galen's acquisition of Warner Chilcott will provide the Irish company with a 260-rep sales force for the U.S. launch of its intravaginal estrogen ring product expected in 2001.

You may also be interested in...



Galen HRT Ring Femring Will Be Approved By February Or March, CEO Predicts

Galen's estradiol ring product Femring will be approved by FDA in February or March, CEO Roger Boissonneault said in an earnings call Feb. 11

Galen HRT Ring Femring Will Be Approved By February Or March, CEO Predicts

Galen's estradiol ring product Femring will be approved by FDA in February or March, CEO Roger Boissonneault said in an earnings call Feb. 11

Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.

Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly

Table

View full table

Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS035992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By